

**Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study**

AUTHORS: Hamill V, Wong S, Benselin J, Kraiden M, Hayes PC, Mutimer D, Yu A, Dillon JF, Gelson W, Velásquez García HA, Yeung A, Johnson P, Barclay ST, Alvarez M, Toyoda H, Agarwal K, Fraser A, Bartlett S, Aldersley M, Bathgate A, Binka M, Richardson P, Morling JR, Ryder SD, MacDonald D, Hutchinson S, Barnes E, Guha IN, Irving W, Janjua NZ, Innes H.

**Table of contents**

**Supplementary Figure 1.....3**

**Supplementary Figure 2.....4**

**Supplementary Figure 3.....5**

**Supplementary Figure 4.....6**

**Supplementary Figure 5.....7**

**Supplementary Figure 6.....8**

**Supplementary Figure 7.....9**

**Supplementary Figure 8.....10**

**Supplementary Figure 9.....11**

**Supplementary Figure 10.....12**

**Supplementary Figure 11.....13**

**Supplementary Figure 12.....14**

**Supplementary Figure 13.....15**

**Supplementary Figure 14.....16**

**Supplementary Figure 15.....17**

**Supplementary Figure 16.....18**

<b>Supplementary Table 1.....</b>	<b>19</b>
<b>Supplementary Table 2.....</b>	<b>20</b>
<b>Supplementary Table 3.....</b>	<b>21</b>
<b>Supplementary Table 4.....</b>	<b>22</b>
<b>Supplementary Table 5.....</b>	<b>23</b>
<b>Supplementary Table 6.....</b>	<b>24</b>
<b>Supplementary Table 7.....</b>	<b>25</b>
<b>Supplementary Table 8.....</b>	<b>26</b>
<b>Supplementary Table 9.....</b>	<b>27</b>
<b>Supplementary Table 10.....</b>	<b>28</b>
<b>Supplementary Table 11.....</b>	<b>29</b>
<b>Supplementary Table 12.....</b>	<b>30</b>
<b>Supplementary Table 13.....</b>	<b>31</b>
<b>Supplementary Table 14.....</b>	<b>32</b>
<b>Supplementary Table 15.....</b>	<b>33</b>
<b>Supplementary Table 16.....</b>	<b>33</b>
<b>Supplementary Table 17.....</b>	<b>34</b>
<b>Supplementary Table 18.....</b>	<b>35</b>
<b>Appendix A.....</b>	<b>36-37</b>
<b>Appendix B.....</b>	<b>37-38</b>

Figure S1. Age at hepatitis C cure: distribution according to setting and liver disease severity




Figure S2. Date of hepatitis C cure: distribution according to setting and liver disease severity






Figure S3. Proportion of individuals with a pre-cure alcohol and substance use hospital admission, by setting and liver disease severity




N.B. All proportions combine recent and historical admissions. The ICD codes used to define these events are outlined in Table S11.

Figure S4. Crude mortality rates for individuals with ESLD (excluding HCC), by cause of death and setting



ESLD refers to End stage liver disease; HCC = hepatocellular carcinoma; PYs= person years


Figure S5. Standardised mortality rates for individuals with ESLD (excluding HCC), by cause of death and setting



Mortality rates are standardized for age and sex, using ESLD patients from BC as the standard population. See Table S12 for further details.


ESLD refers to End stage liver disease. HCC refers to hepatocellular carcinoma; PYs refers to person years

Figure S6. Crude mortality rates for pre-cirrhosis individuals, by cause of death and setting




N.B. mortality data for pre-cirrhosis patients were not available in our England cohort.  
 PYs = person years

Figure S7. Crude mortality rates for individuals with compensated cirrhosis, by cause of death and setting




PYs = person years

Figure S8. Crude mortality rates for individuals with end stage liver disease, by cause of death and setting



PYs = person years

Figure S9. Standardised mortality rates for pre-cirrhosis individuals, by cause of death and setting




Mortality rates are standardized for age and sex, using pre-cirrhosis patients from BC as the standard population. See Table S12 for further details.

N.B. mortality data for pre-cirrhosis patients were not available in our England cohort.

PYs=person years


Figure S10. Standardised mortality rates for individuals with compensated cirrhosis, by cause of death and setting



Mortality rates are standardized for age and sex, using compensated cirrhosis patients from BC as the standard population. See Table S12 for further details.

PYs = person years


Figure S11. Standardised mortality rates for individuals with ESLD, by cause of death and setting



Mortality rates are standardized for age and sex, using ESLD patients from BC as the standard population. See Table S12 for further details.

ESLD refers to End stage liver disease; PYs = person years

Figure S12. Standardised mortality ratio (SMR) for pre-cirrhosis individuals, by cause of death and setting




\*Expected deaths indicates the number of deaths that would have occurred if cured patients exhibited the same age/sex/year specific mortality rates as the corresponding general population.

† SMR is the ratio of observed to expected deaths. Values above 1 indicate excess mortality (i.e. no. deaths observed exceed no. deaths expected).

N.B. mortality data for pre-cirrhosis patients were not available in the England cohort.


Figure S13. Standardised mortality ratio (SMR) for individuals with compensated cirrhosis, by cause of death and setting.



\*Expected deaths indicates the number of deaths that would have occurred if cured patients exhibited the same age/sex/year specific mortality rates as the corresponding general population.

† SMR is the ratio of observed to expected deaths. Values above 1 indicate excess mortality (i.e. no. deaths observed exceed no. deaths expected).


Figure S14. Standardised mortality ratio (SMR) for individuals with end-stage-liver-disease, by cause of death and setting



\*Expected deaths indicates the number of deaths that would have occurred if cured patients exhibited the same age/sex/year specific mortality rates as the corresponding general population.

† SMR is the ratio of observed to expected deaths. Values above 1 indicate excess mortality (i.e. no. deaths observed exceed no. deaths expected).

Figure S15. Standardised mortality ratios (SMR) for all-cause mortality in Scotland, with and without adjustment for area-based deprivation




\*SIMD = Scottish index multiple deprivation. A small fraction of individuals with missing SIMD data were excluded from the SIMD adjusted estimate.

† SMR is the ratio of observed to expected deaths. Values above 1 indicate excess mortality (i.e. no. deaths observed exceed no. deaths expected).

‡ Null hypothesis is that SMR =1 (represented by the dashed vertical line).

N.B. It was not possible to perform the equivalent adjustment in our BC or English cohort.

Figure S16. Non-linear relationship observed between Charlson Comorbidity Index (CCI) and mortality among pre-cirrhosis patients in British Columbia.



The modelled mortality rate and SMR in this figure are derived from the multivariate regression models shown in Table 2 and Table S17, respectively. The non-linear relationship represented by a first order fractional polynomial power term of -2. Predicted estimates relate specifically to males, without a previous hospital admission for alcohol or substance use, with mean age and mean year of SVR achievement.

Table S1. All-cause mortality rate (deaths per 100,000) in the general population, by age group, year, sex and setting.

**British Columbia**

Year - Sex	Age group, years											
	10-19	20-29	30-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
2014 M	30.0	80.9	104.5	144.3	230.4	341.6	586.4	879.9	1224.0	2142.9	3320.1	9152.8
2014 F	12.7	32.6	55.1	99.2	133.0	221.6	303.5	492.8	825.5	1292.9	2228.4	8213.9
2015 M	29.8	94.4	120.9	147.0	230.1	346.9	569.0	840.0	1220.6	1989.9	3213.4	9590.4
2015 F	15.2	32.9	46.9	84.3	117.7	196.9	337.6	537.3	783.2	1372.1	2294.4	8463.2
2016 M	32.0	114.7	149.0	196.1	254.1	361.1	542.2	865.3	1393.4	1931.3	3326.5	9505.9
2016 F	19.5	42.8	58.8	80.9	138.9	234.0	363.9	520.1	779.5	1301.2	2277.9	8333.1
2017 M	33.1	132.8	183.1	205.1	298.9	398.3	580.1	887.7	1325.4	2008.7	3312.4	9766.0
2017 F	22.0	42.7	66.5	94.4	154.7	229.3	327.3	480.3	773.7	1319.4	2241.4	8600.0
2018 M	38.0	127.3	180.3	223.3	272.5	412.3	608.6	900.6	1264.0	1961.5	3190.7	9281.6
2018 F	16.9	48.9	73.9	90.6	132.1	216.7	323.6	517.9	740.1	1204.1	2154.6	8359.2
2019 M	26.3	103.0	147.0	176.7	254.0	381.3	547.7	810.3	1275.2	1900.2	3106.0	9223.1
2019 F	21.1	42.4	66.7	98.3	163.4	199.8	320.7	489.0	729.8	1191.2	2223.2	8269.6

**Scotland**

Year - Sex	Age group, years											
	10-19	20-29	30-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
2014 M	23.9	71.9	145.4	271.0	336.5	465.0	724.1	1146.6	1771.9	2980.6	4794.9	11620.0
2014 F	14.8	32.5	69.1	149.8	209.8	308.0	505.5	750.8	1176.4	1941.7	3482.9	10361.4
2015 M	24.4	70.3	160.0	260.9	355.5	481.7	743.8	1163.7	1862.2	3150.4	4901.9	12209.2
2015 F	11.0	29.7	87.8	143.0	229.1	326.3	484.0	719.5	1217.0	2100.4	3475.9	11099.2
2016 M	28.0	84.8	160.1	327.4	381.7	517.7	761.9	1149.6	1846.7	2915.9	4686.4	11769.3
2016 F	16.1	34.8	87.8	167.3	218.4	319.7	489.3	779.3	1170.9	2026.0	3486.0	10512.2
2017 M	24.7	73.9	175.8	279.0	400.1	503.6	714.5	1128.6	1779.2	2827.1	4975.4	12040.4
2017 F	16.5	27.9	90.0	161.3	205.4	332.0	497.2	764.8	1209.3	1955.9	3610.1	10841.6
2018 M	31.1	90.0	170.4	308.5	407.1	497.3	733.3	1118.0	1775.7	2668.4	4808.3	11680.3
2018 F	17.5	34.2	88.8	164.3	216.3	344.8	483.4	762.2	1204.6	1951.5	3431.0	10474.2
2019 M	26.5	87.4	171.4	333.6	408.4	508.9	682.0	1113.6	1714.0	2651.5	4588.9	11388.1
2019 F	16.7	38.3	88.1	186.3	233.6	316.2	492.7	777.7	1209.8	1861.2	3320.2	10321.3

**England**

Year - Sex	Age group, years											
	10-19	20-29	30-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
2014 M	19.6	51.3	89.7	163.8	241.7	353.0	568.9	928.6	1400.3	2349.6	3930.0	10825.3
2014 F	11.5	23.7	53.3	105.4	155.3	241.1	376.1	603.3	909.6	1565.7	2709.4	9660.4
2015 M	19.9	54.2	93.6	168.7	247.3	369.8	577.1	940.8	1420.5	2337.2	4012.9	11242.4
2015 F	12.5	23.9	52.4	101.2	160.1	245.5	377.0	603.0	932.8	1560.3	2769.7	10282.3
2016 M	19.4	53.6	96.3	172.1	253.8	367.4	577.2	935.4	1449.6	2324.8	4038.7	11000.5
2016 F	12.2	25.3	58.3	107.1	164.5	252.3	394.3	614.8	948.3	1577.1	2780.1	9918.9
2017 M	21.3	54.4	97.7	175.0	260.7	375.2	569.9	919.1	1434.2	2268.0	3979.0	11002.7
2017 F	12.4	23.2	53.5	104.6	159.9	245.6	366.8	599.5	935.3	1503.3	2770.7	9996.9
2018 M	19.4	57.3	99.1	170.7	257.0	383.3	570.4	896.7	1435.1	2220.2	3862.7	10779.2
2018 F	11.9	26.0	55.9	101.5	169.5	241.7	383.5	592.8	922.3	1491.3	2692.4	9799.4
2019 M	19.6	54.1	100.1	166.1	260.7	380.9	563.5	874.5	1413.2	2174.9	3758.1	10534.5
2019 F	10.6	24.1	55.6	100.9	162.7	245.4	367.9	583.2	896.1	1464.6	2583.0	9397.2

Table S2. Mortality rate for primary liver cancer (deaths per 100,000) in the general population, by age group, year, sex and setting.

<b>British Columbia</b>												
Year - Sex	Age group, years											
	10-19	20-29	30-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
2014 M	0.0	0.3	0.3	0.0	0.0	5.4	26.7	38.9	32.3	45.7	66.0	68.1
2014 F	0.0	0.0	0.0	0.0	1.2	2.6	5.6	7.7	11.4	20.1	22.8	49.0
2015 M	0.0	0.3	0.9	2.0	5.4	8.1	20.5	43.1	39.4	50.3	24.4	70.8
2015 F	0.0	0.0	0.0	0.0	1.7	2.6	3.8	8.0	12.9	30.4	34.6	37.7
2016 M	0.0	0.3	0.9	1.3	4.2	7.7	13.9	40.5	46.3	41.8	38.3	74.4
2016 F	0.0	0.0	0.0	1.3	1.1	4.8	3.7	5.9	10.9	21.3	21.3	38.6
2017 M	0.0	0.6	1.2	0.7	2.4	7.9	15.4	34.7	40.8	45.1	70.3	74.4
2017 F	0.0	0.0	0.3	1.3	0.0	2.7	5.8	10.3	10.0	16.8	14.1	57.8
2018 M	0.0	0.0	0.3	1.3	1.8	5.2	14.2	35.6	43.7	39.7	55.8	66.8
2018 F	0.0	0.0	0.3	0.6	1.2	2.8	6.8	10.0	14.3	17.4	23.1	44.2
2019 M	0.0	0.0	0.6	1.3	1.3	4.2	15.2	30.3	48.9	39.4	49.0	66.6
2019 F	0.0	0.0	0.6	1.9	1.2	3.4	6.2	11.5	15.8	15.7	27.7	45.6

<b>Scotland</b>												
Year - Sex	Age group, years											
	10-19	20-29	30-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
2014 M	0.0	0.0	0.6	0.6	2.0	3.1	15.0	20.1	41.3	56.5	61.0	106.4
2014 F	0.0	0.3	0.0	1.6	2.9	3.4	5.0	5.6	12.7	21.9	36.4	47.6
2015 M	0.0	0.6	0.3	1.2	4.2	10.1	12.4	17.5	39.6	51.0	60.5	113.3
2015 F	0.0	0.0	0.0	0.6	1.0	2.9	8.1	8.6	19.2	23.3	38.1	54.3
2016 M	0.0	0.0	0.3	1.2	3.7	8.1	17.7	23.0	40.4	51.0	76.4	99.5
2016 F	0.0	0.3	0.0	0.6	0.5	5.7	5.3	10.3	13.4	23.6	44.1	45.9
2017 M	0.0	0.3	0.6	0.0	2.7	7.6	14.1	18.8	36.6	45.8	89.7	116.3
2017 F	0.0	0.0	0.0	0.6	3.5	2.9	6.7	12.4	19.7	27.0	44.0	57.2
2018 M	0.3	0.3	0.3	0.6	5.0	4.6	11.2	24.5	36.6	54.5	71.7	111.4
2018 F	0.0	0.0	0.0	1.2	1.0	1.9	5.0	10.4	17.4	18.9	25.5	46.9
2019 M	0.0	0.0	0.3	0.0	2.9	6.2	10.5	26.4	33.9	53.7	74.0	107.9
2019 F	0.0	0.3	0.0	0.6	2.1	2.9	6.9	8.4	11.6	19.1	35.2	50.9

<b>England</b>												
Year - Sex	Age group, years											
	10-19	20-29	30-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
2014 M	0.1	0.1	0.4	1.2	2.6	4.9	10.8	16.5	25.7	33.7	47.8	74.5
2014 F	0.0	0.1	0.2	0.6	1.0	2.1	5.0	7.7	13.1	19.8	28.7	44.3
2015 M	0.0	0.1	0.4	0.9	2.0	5.2	9.0	18.2	24.9	37.1	51.3	69.3
2015 F	0.1	0.1	0.2	0.7	1.4	2.7	4.5	6.8	11.5	18.1	27.9	46.5
2016 M	0.1	0.2	0.3	1.1	2.4	5.7	10.5	18.0	27.0	35.8	53.9	72.8
2016 F	0.0	0.1	0.3	0.4	0.9	3.1	4.4	8.9	12.6	21.5	27.9	43.5
2017 M	0.1	0.1	0.5	1.4	2.4	5.7	11.3	18.2	27.4	38.5	56.4	76.5
2017 F	0.0	0.1	0.3	0.8	1.3	2.7	4.9	10.5	13.5	18.0	32.1	43.6
2018 M	0.0	0.1	0.3	1.2	2.2	5.5	9.8	18.7	29.3	38.6	55.8	78.4
2018 F	0.0	0.1	0.3	0.5	1.5	2.1	4.5	8.9	14.2	19.9	28.9	42.9
2019 M	0.1	0.1	0.5	0.9	2.2	5.1	10.4	19.3	28.6	41.8	53.7	76.3
2019 F	0.0	0.1	0.5	0.9	1.7	2.6	5.5	7.6	14.7	21.9	28.9	47.9

Table S3. Mortality rate for liver failure (deaths per 100,000) in the general population, by age group, year, sex and setting.

**British Columbia**

Year - Sex	Age group, years											
	10-19	20-29	30-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
2014 M	0.0	0.9	1.9	5.8	10.8	25.6	42.4	60.7	57.6	42.3	45.6	33.4
2014 F	0.0	0.3	2.2	4.3	8.7	15.3	24.6	19.2	24.4	32.8	38.4	25.7
2015 M	0.0	1.2	3.2	8.5	15.1	28.1	32.4	60.4	49.1	57.7	41.1	46.4
2015 F	0.0	0.0	2.2	5.6	8.7	11.0	21.2	27.0	25.0	29.4	34.6	21.3
2016 M	0.0	0.3	3.7	5.9	12.0	27.9	29.0	43.0	62.0	45.9	33.9	42.8
2016 F	0.0	0.3	3.0	5.0	8.5	16.9	27.6	27.1	23.1	38.6	21.3	26.6
2017 M	0.0	0.6	2.1	7.3	8.5	24.1	27.6	42.6	58.4	46.0	33.7	47.0
2017 F	0.0	0.9	3.9	3.2	8.0	16.2	15.8	18.9	25.3	28.4	29.5	27.7
2018 M	0.0	1.1	3.2	9.9	13.5	27.8	32.7	53.5	60.3	45.0	41.2	48.8
2018 F	0.0	0.9	2.9	6.3	6.9	11.6	19.8	24.0	25.4	21.5	31.7	25.6
2019 M	0.0	0.3	2.8	10.3	16.8	22.6	29.8	39.7	54.4	54.5	47.8	46.1
2019 F	0.4	1.2	3.9	3.7	12.9	14.6	15.5	20.8	27.2	32.9	24.2	29.6

**Scotland**

Year - Sex	Age group, years											
	10-19	20-29	30-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
2014 M	0.0	1.1	10.9	23.4	31.2	39.1	56.6	55.2	65.7	61.2	35.4	43.9
2014 F	0.0	0.6	5.7	13.5	20.2	20.6	31.9	26.6	25.3	18.6	32.6	27.0
2015 M	0.3	0.6	7.9	18.2	39.7	41.1	49.7	64.8	60.7	48.2	52.0	33.1
2015 F	0.0	0.5	5.9	12.3	22.0	23.6	35.5	25.2	32.2	37.8	29.6	27.5
2016 M	0.0	1.4	7.2	23.7	30.6	48.1	64.2	65.2	60.0	66.2	54.5	48.7
2016 F	0.0	0.8	5.8	13.9	17.8	28.2	26.3	29.7	31.7	29.1	43.1	27.1
2017 M	0.0	0.8	7.9	17.6	39.9	46.1	54.7	63.2	69.9	59.7	47.8	53.6
2017 F	0.0	0.8	4.2	11.5	18.5	22.4	34.5	26.6	36.2	40.1	23.9	26.7
2018 M	0.0	0.3	5.5	25.7	33.2	36.3	53.2	45.3	72.4	67.0	47.0	51.3
2018 F	0.0	0.8	5.0	11.1	17.6	22.5	31.7	34.7	29.0	35.1	33.9	33.3
2019 M	0.0	0.8	5.4	19.1	27.5	35.6	44.0	49.7	65.8	44.6	48.9	49.7
2019 F	0.0	0.3	3.8	12.9	14.5	22.2	36.1	40.5	37.4	33.4	30.5	34.5

**England**

Year - Sex	Age group, years											
	10-19	20-29	30-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
2014 M	0.0	0.6	6.7	16.3	26.4	32.7	38.8	46.3	41.7	36.7	37.9	34.3
2014 F	0.0	0.4	4.3	9.8	14.2	17.5	20.7	22.0	20.1	23.0	25.6	20.9
2015 M	0.2	0.5	6.5	17.5	27.1	34.6	41.4	45.1	44.2	37.3	36.2	33.7
2015 F	0.0	0.4	4.7	10.4	14.1	17.2	21.9	25.2	22.9	23.6	25.4	22.7
2016 M	0.1	0.8	6.8	16.6	28.4	34.1	41.8	44.1	45.7	39.3	40.0	38.3
2016 F	0.0	0.7	3.9	10.3	15.6	17.6	20.9	24.4	21.5	24.0	26.4	23.2
2017 M	0.0	0.9	5.6	18.3	27.3	32.9	41.5	47.2	47.2	37.3	42.7	36.7
2017 F	0.0	0.5	4.5	11.2	14.2	17.6	22.5	24.8	23.0	20.9	26.5	23.3
2018 M	0.1	0.7	5.8	15.2	25.4	33.8	39.8	42.2	44.1	42.2	36.1	40.0
2018 F	0.0	0.5	3.9	8.3	14.1	17.2	19.7	25.9	23.8	23.7	25.4	22.5
2019 M	0.1	0.5	4.8	14.4	25.8	35.1	42.1	46.0	43.5	39.9	42.3	34.9
2019 F	0.0	0.4	3.8	9.7	15.2	18.8	21.3	23.7	24.5	24.4	23.8	24.1

Table S4. Drug-related mortality rate (deaths per 100,000) in the general population, by age group, year, sex and setting.

**British Columbia**

Year - Sex	Age group, years											
	10-19	20-29	30-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
2014 M	2.3	19.3	27.3	23.0	28.9	27.2	23.8	20.5	10.3	2.2	9.4	7.2
2014 F	0.4	8.9	13.0	10.4	15.7	10.6	15.1	9.0	7.6	4.2	4.3	7.5
2015 M	3.4	23.9	37.2	33.8	32.6	31.4	35.8	26.4	11.2	4.3	6.1	11.6
2015 F	1.2	11.4	10.6	15.5	14.4	18.4	9.2	8.0	4.3	4.1	2.8	5.7
2016 M	4.6	46.4	68.2	70.7	64.3	63.9	49.0	21.2	18.5	3.1	1.5	10.1
2016 F	5.7	14.5	16.7	14.4	19.9	23.2	20.7	13.5	6.1	2.9	5.3	1.6
2017 M	7.2	63.9	102.8	82.7	109.5	90.9	60.1	54.8	16.9	8.5	5.6	3.3
2017 F	6.8	14.7	21.1	22.7	25.1	18.9	18.4	14.3	6.0	2.7	2.6	4.8
2018 M	7.5	41.6	62.8	55.2	58.2	71.3	54.0	31.5	16.0	8.8	6.6	3.2
2018 F	2.4	15.0	18.5	12.0	20.8	18.2	15.1	11.2	3.3	2.5	7.3	3.1
2019 M	1.1	9.2	18.0	14.8	14.9	16.1	10.3	12.8	10.2	4.2	2.5	4.1
2019 F	4.3	4.8	7.0	8.1	7.6	3.9	10.3	7.1	2.5	3.1	3.5	1.5

**Scotland**

Year - Sex	Age group, years											
	10-19	20-29	30-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
2014 M	3.4	24.7	50.5	58.8	36.8	32.9	10.4	5.2	4.7	5.7	2.4	0.0
2014 F	1.8	6.8	17.9	17.2	14.0	10.8	8.8	5.0	3.8	2.4	1.9	0.6
2015 M	1.7	18.1	51.6	52.9	42.8	26.9	16.4	7.8	7.9	3.7	6.1	1.1
2015 F	0.7	4.4	24.1	26.7	21.5	17.3	11.3	11.1	2.5	0.8	5.7	1.9
2016 M	3.8	22.6	61.2	91.0	51.2	27.9	15.5	10.2	9.1	0.9	1.2	4.1
2016 F	2.9	8.9	22.8	34.2	26.6	16.7	11.1	8.5	3.1	6.3	3.8	3.8
2017 M	2.7	22.5	64.3	83.4	67.4	41.0	17.3	10.6	8.1	4.9	3.6	1.0
2017 F	2.2	5.7	29.1	41.1	24.6	20.0	15.4	5.9	5.1	5.8	2.9	1.2
2018 M	6.2	32.1	72.0	113.8	98.0	55.7	22.3	13.5	7.6	3.1	4.7	3.0
2018 F	2.2	8.2	30.5	43.2	31.0	22.5	12.6	9.8	8.4	1.4	0.9	1.9
2019 M	4.8	30.0	67.3	119.9	107.0	63.9	26.7	15.0	4.2	3.8	5.7	2.9
2019 F	3.6	12.1	30.0	56.0	40.2	26.6	15.8	9.0	7.1	2.1	1.9	0.0

**England**

Year - Sex	Age group, years											
	10-19	20-29	30-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
2014 M	0.8	7.5	16.9	19.0	15.6	10.8	7.4	5.9	3.3	2.8	3.0	3.6
2014 F	0.5	2.5	5.8	7.3	6.1	6.9	4.8	4.3	3.3	2.5	1.9	2.5
2015 M	0.8	7.9	19.1	22.8	19.1	13.2	9.2	5.9	3.8	3.0	1.9	3.7
2015 F	0.5	2.4	6.1	8.8	7.8	7.1	5.1	4.1	2.3	2.3	2.7	2.9
2016 M	0.8	8.2	19.3	23.5	18.9	12.3	9.6	7.3	3.0	2.7	2.4	3.7
2016 F	0.8	3.4	6.8	9.0	9.1	7.0	6.8	5.2	4.0	2.3	3.1	3.1
2017 M	1.0	8.2	17.9	25.5	21.7	16.0	9.8	6.2	4.8	2.2	2.2	3.9
2017 F	0.8	3.0	6.5	9.3	9.2	7.6	4.4	4.7	3.5	2.9	2.6	3.0
2018 M	1.1	10.0	20.3	26.6	24.7	16.8	10.8	7.6	4.4	2.5	2.8	4.9
2018 F	0.6	3.3	7.8	10.1	10.3	9.0	6.1	6.3	3.7	2.3	3.1	2.5
2019 M	1.2	8.6	19.3	27.1	29.0	19.9	13.1	7.1	4.7	2.6	2.4	4.3
2019 F	0.6	3.5	7.8	10.4	10.6	10.4	8.3	6.8	3.9	3.7	2.7	3.3

Table S5. Mortality rate for external causes (deaths per 100,000) in the general population, by age group, year, sex and setting.

**British Columbia**

Year - Sex	Age group, years											
	10-19	20-29	30-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
2014 M	21.3	40.9	37.6	46.0	51.7	51.7	63.9	58.7	40.2	72.4	100.5	278.2
2014 F	6.6	11.4	9.8	11.6	8.1	15.8	8.9	19.2	19.8	38.1	61.2	224.0
2015 M	16.8	45.1	37.2	39.7	45.9	53.0	67.6	56.6	48.4	66.3	108.2	303.0
2015 F	6.1	10.5	7.8	9.3	11.5	9.5	20.1	10.4	15.7	24.3	52.6	243.2
2016 M	17.5	42.0	37.2	39.0	49.3	42.6	47.3	59.1	60.5	64.2	101.6	268.2
2016 F	7.3	15.1	10.0	11.3	12.0	12.2	13.8	14.1	18.3	32.8	52.0	195.5
2017 M	16.3	35.9	33.8	35.1	36.9	32.0	53.4	41.4	44.3	66.7	92.8	241.8
2017 F	5.6	9.7	9.8	12.0	12.6	13.5	7.9	14.3	14.0	25.7	39.7	188.3
2018 M	12.8	33.3	33.0	31.5	41.6	44.7	45.8	46.9	49.2	52.0	77.0	257.6
2018 F	7.1	11.6	12.1	6.9	7.5	16.6	13.0	17.3	14.3	18.2	39.0	203.9
2019 M	11.7	32.1	28.0	32.3	31.8	41.6	37.9	40.8	43.5	58.7	96.8	257.1
2019 F	8.2	10.5	5.9	5.6	11.8	9.6	8.8	11.5	16.4	17.2	41.5	210.4

**Scotland**

Year - Sex	Age group, years											
	10-19	20-29	30-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
2014 M	11.8	28.9	32.2	47.4	43.9	38.6	42.8	44.8	46.7	55.6	86.6	281.8
2014 F	3.5	10.4	9.8	11.9	15.9	13.2	13.2	17.9	23.4	25.1	58.4	272.4
2015 M	12.9	30.2	38.2	47.0	43.3	42.6	44.1	41.5	52.2	67.6	90.7	284.3
2015 F	2.1	7.6	8.8	12.3	16.7	13.9	16.7	20.3	17.3	24.1	54.4	292.5
2016 M	10.2	36.7	38.4	58.2	48.0	46.1	44.3	43.5	45.6	71.5	116.3	340.9
2016 F	5.7	11.1	11.3	10.4	15.3	11.5	14.2	14.5	22.6	29.9	65.2	292.5
2017 M	11.3	33.6	42.9	47.7	49.1	48.6	49.3	44.4	40.7	60.5	116.0	322.6
2017 F	2.9	6.8	8.8	10.3	14.5	15.7	12.9	17.7	20.3	28.4	79.3	335.2
2018 M	14.4	35.1	41.6	41.1	54.8	48.5	44.1	41.7	50.3	49.9	97.6	326.3
2018 F	3.6	8.8	9.4	11.7	13.4	13.9	12.6	17.9	25.1	32.3	54.7	303.3
2019 M	11.9	38.4	43.4	56.8	53.2	43.3	50.9	43.8	51.2	65.7	111.5	335.1
2019 F	5.3	10.8	9.5	8.0	13.4	13.0	24.2	14.1	17.4	31.4	62.9	343.9

**England**

Year - Sex	Age group, years											
	10-19	20-29	30-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
2014 M	8.1	24.0	23.8	33.0	35.1	32.1	32.1	34.6	30.7	45.1	73.6	233.2
2014 F	3.2	6.3	6.9	8.0	9.7	11.1	11.8	12.6	15.8	25.2	46.9	197.5
2015 M	8.3	25.3	26.0	34.0	34.1	34.3	33.8	35.4	35.3	46.1	83.8	267.7
2015 F	3.4	6.1	6.5	7.8	9.8	11.7	11.4	14.0	16.9	26.4	52.1	219.9
2016 M	8.7	24.2	26.9	32.9	34.6	33.9	34.6	34.7	38.5	47.8	83.0	263.0
2016 F	3.2	5.9	7.8	8.7	10.7	11.9	11.5	13.9	16.6	25.9	51.8	213.1
2017 M	9.5	25.2	29.8	32.1	36.2	35.7	33.9	36.2	38.6	50.4	85.4	278.1
2017 F	4.0	6.5	6.5	8.2	9.4	10.0	11.4	14.9	17.0	28.7	54.4	228.3
2018 M	8.7	26.6	28.2	31.8	37.6	37.3	34.5	37.9	38.3	50.7	89.3	282.1
2018 F	3.8	7.3	7.3	9.0	10.8	10.9	13.8	15.5	19.8	29.0	55.0	225.9
2019 M	7.8	24.4	29.7	32.1	37.6	35.9	32.4	36.5	38.2	49.7	82.6	272.9
2019 F	3.1	6.6	7.0	8.6	10.8	9.9	12.2	13.4	18.1	25.9	50.5	224.4

Table S6. Mortality rate for extrahepatic cancer (deaths per 100,000) in the general population, by age group, year, sex and setting.

**British Columbia**

Year - Sex	Age group, years											
	10-19	20-29	30-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
2014 M	2.7	6.0	13.5	24.9	49.3	99.5	193.3	322.6	511.8	853.1	1168.5	2206.4
2014 F	2.5	5.4	14.3	44.7	61.5	110.3	151.5	265.6	447.4	605.2	878.5	1334.0
2015 M	3.8	4.8	12.6	18.2	45.9	90.4	179.6	298.9	475.6	791.3	1144.3	2104.8
2015 F	1.6	4.1	13.4	32.2	45.0	96.6	182.7	288.6	390.6	666.8	840.5	1374.7
2016 M	4.2	3.0	7.6	25.8	41.4	82.5	160.9	298.8	531.2	713.4	1211.9	2097.9
2016 F	1.6	3.2	12.7	27.6	52.9	109.9	170.3	279.5	391.1	574.8	851.2	1389.7
2017 M	2.3	9.6	10.1	21.2	42.4	88.6	169.1	315.8	512.2	767.6	1100.4	2130.0
2017 F	2.4	3.1	13.7	32.7	62.8	104.7	160.5	247.0	373.6	595.4	881.2	1363.2
2018 M	1.9	4.3	9.5	18.4	42.3	84.7	176.1	297.6	462.5	749.7	1128.2	2058.6
2018 F	1.2	4.0	9.8	30.8	46.7	81.3	167.8	248.6	349.6	527.5	784.4	1368.9
2019 M	4.9	5.9	11.4	20.0	45.5	92.2	168.5	278.3	480.3	704.7	1091.1	2070.0
2019 F	2.4	3.0	12.1	33.0	61.7	83.3	167.6	244.8	350.7	541.6	799.8	1345.6

**Scotland**

Year - Sex	Age group, years											
	10-19	20-29	30-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
2014 M	2.7	2.8	12.4	37.7	69.4	127.6	253.1	471.1	730.8	1187.5	1697.1	2810.7
2014 F	3.5	4.1	16.4	53.9	78.0	144.0	242.3	361.2	540.1	861.1	1183.3	1829.3
2015 M	3.7	5.8	14.4	36.4	71.5	137.4	253.6	461.6	767.1	1206.4	1683.1	2774.4
2015 F	1.8	6.8	20.3	36.7	89.1	144.2	220.7	333.0	550.6	868.9	1139.6	1825.9
2016 M	2.1	6.0	13.2	41.8	86.1	127.6	232.9	444.4	740.2	1106.7	1594.9	2826.8
2016 F	2.5	5.1	21.4	56.2	75.9	134.3	227.3	330.0	517.5	818.7	1155.0	1817.5
2017 M	3.8	2.7	14.1	37.0	71.7	117.0	215.6	408.9	699.6	1114.8	1672.0	2942.8
2017 F	3.2	3.8	19.8	38.7	73.1	151.2	219.8	329.4	547.9	787.3	1248.9	1813.2
2018 M	4.1	3.8	14.3	32.8	67.6	119.0	243.0	427.0	687.5	1028.4	1699.2	2668.7
2018 F	2.5	3.6	21.1	45.1	69.2	144.6	227.6	350.2	540.5	825.3	1162.5	1771.9
2019 M	2.0	3.8	15.2	42.1	60.6	121.2	224.9	424.3	668.0	1019.4	1597.5	2764.0
2019 F	2.5	4.1	19.4	49.8	78.2	130.3	216.5	362.7	550.4	774.7	1188.2	1814.1

**England**

Year - Sex	Age group, years											
	10-19	20-29	30-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
2014 M	3.0	5.3	12.2	30.0	57.2	111.5	219.0	391.4	617.0	967.2	1424.2	2639.7
2014 F	2.1	5.6	18.1	43.2	72.0	120.7	198.1	314.8	456.2	684.7	937.5	1602.9
2015 M	3.2	5.2	13.0	28.5	56.6	109.2	212.8	387.0	614.7	955.9	1415.7	2602.5
2015 F	2.2	5.1	17.8	39.4	72.2	120.4	195.5	307.4	458.0	666.5	955.6	1587.6
2016 M	2.8	5.1	13.0	29.2	57.3	111.6	206.4	377.2	613.1	931.9	1430.6	2585.6
2016 F	2.4	5.1	19.3	41.0	71.2	122.3	201.5	301.5	464.2	672.2	982.1	1579.3
2017 M	2.8	4.6	12.6	31.7	58.1	110.3	200.6	366.4	598.6	910.6	1399.5	2554.4
2017 F	2.4	4.0	18.0	39.5	69.0	118.3	183.1	293.9	449.5	652.6	945.9	1571.7
2018 M	3.2	4.9	13.4	27.9	56.4	109.6	198.4	346.2	587.4	870.0	1356.8	2487.6
2018 F	2.0	5.4	18.8	37.0	72.6	111.9	193.3	288.8	432.1	635.9	924.6	1531.9
2019 M	2.4	5.1	14.1	27.8	53.2	106.5	186.1	337.5	574.1	858.4	1325.6	2474.3
2019 F	1.8	4.2	17.6	37.2	69.4	116.9	178.0	281.7	413.9	629.1	898.5	1552.2

Table S7. Mortality rate for circulatory disease (deaths per 100,000) in the general population, by age group, year, sex and setting.

<b>British Columbia</b>												
Year - Sex	Age group, years											
	10-19	20-29	30-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
2014 M	0.4	1.5	6.4	16.0	47.5	59.8	106.2	171.5	250.0	476.7	871.6	2989.6
2014 F	1.2	1.0	4.4	10.4	16.3	24.8	33.0	67.2	121.2	202.1	522.6	3008.1
2015 M	0.0	3.9	6.9	14.3	39.9	64.4	115.4	174.2	265.0	426.6	748.1	3182.1
2015 F	0.8	1.9	4.0	3.7	11.0	17.3	34.8	66.9	123.5	229.7	508.2	3045.7
2016 M	0.0	5.3	8.2	23.1	30.6	67.2	121.9	183.7	306.9	439.3	795.2	3127.7
2016 F	0.8	1.9	3.6	5.6	17.1	21.7	40.8	58.3	113.9	228.0	504.9	3040.8
2017 M	0.4	2.6	8.6	19.9	39.9	72.9	117.9	194.1	296.9	449.1	805.3	3191.2
2017 F	0.4	2.5	3.3	6.9	16.0	25.9	47.4	62.9	107.9	233.0	509.8	3035.7
2018 M	1.1	2.9	12.3	22.3	30.6	58.6	120.5	199.0	276.0	482.4	773.8	2952.2
2018 F	0.0	0.9	4.9	11.3	11.5	24.9	29.7	64.7	110.0	223.6	468.9	2900.6
2019 M	0.0	3.1	8.6	19.4	34.9	61.3	111.6	169.2	262.2	416.1	711.5	2882.2
2019 F	0.4	3.3	3.4	10.6	16.5	22.5	27.4	63.0	112.5	204.3	473.7	2853.0

<b>Scotland</b>												
Year - Sex	Age group, years											
	10-19	20-29	30-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
2014 M	0.0	4.7	15.5	54.2	79.1	129.6	185.5	295.2	482.3	834.4	1429.9	3679.2
2014 F	0.4	1.6	6.9	22.1	31.3	48.5	88.1	120.6	240.6	418.0	911.4	3300.7
2015 M	0.7	2.8	21.7	52.9	79.9	122.7	194.3	318.3	493.1	894.2	1397.8	3823.9
2015 F	0.7	1.9	10.6	19.5	32.8	48.1	66.2	121.7	235.3	471.9	927.9	3430.9
2016 M	0.7	4.6	14.4	49.1	80.8	138.3	221.3	299.9	478.9	809.0	1367.0	3576.0
2016 F	0.4	1.9	11.0	23.7	28.1	44.9	76.8	138.7	231.0	444.4	871.3	3165.0
2017 M	1.0	4.3	19.4	43.9	89.0	125.1	209.1	322.6	505.5	756.8	1418.5	3439.4
2017 F	1.4	2.2	8.8	26.6	27.1	55.3	76.2	143.7	227.7	423.5	848.5	3139.4
2018 M	1.0	3.8	14.1	47.6	74.2	123.0	194.6	305.1	460.0	738.6	1299.4	3449.5
2018 F	0.7	2.2	5.0	18.5	26.8	56.0	67.5	124.8	220.7	387.1	837.3	2919.3
2019 M	0.3	2.7	15.8	45.9	76.1	137.7	187.1	288.9	456.2	700.5	1293.7	3303.4
2019 F	1.1	3.9	7.9	17.8	40.7	44.9	74.6	137.8	231.6	384.9	786.6	2896.7

<b>England</b>												
Year - Sex	Age group, years											
	10-19	20-29	30-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
2014 M	1.1	3.2	12.6	35.1	59.8	97.2	159.8	250.1	370.2	652.4	1128.4	3249.1
2014 F	0.7	2.0	5.8	15.4	23.0	35.8	58.7	97.3	162.4	328.8	684.7	2877.3
2015 M	1.3	4.0	11.2	32.4	60.7	101.1	158.7	257.5	377.3	631.1	1129.5	3234.8
2015 F	0.5	2.0	5.8	14.1	23.9	35.3	58.6	103.6	169.9	332.3	670.4	2880.4
2016 M	1.5	3.8	12.9	34.3	62.6	96.9	156.7	253.4	381.0	627.5	1091.9	3082.3
2016 F	0.7	2.0	6.4	13.7	24.3	38.2	60.4	104.7	166.6	317.2	643.8	2706.6
2017 M	1.2	4.1	12.7	34.2	60.0	101.6	160.9	247.7	368.4	593.8	1051.7	3032.9
2017 F	0.8	2.0	5.6	14.6	22.5	38.4	54.8	101.8	166.9	298.1	651.4	2633.6
2018 M	1.0	3.5	12.9	34.6	60.5	101.4	159.0	244.6	374.5	581.0	993.3	2893.9
2018 F	1.0	2.5	5.4	14.6	25.0	36.0	59.0	98.3	166.8	286.8	593.1	2486.2
2019 M	1.1	3.1	12.2	32.9	61.6	102.6	158.2	237.1	368.1	572.6	985.8	2808.0
2019 F	0.8	2.0	6.0	13.5	22.3	34.4	60.2	101.2	164.5	279.8	569.0	2398.2

Table S8. Mortality rate for other causes of death (deaths per 100,000) in the general population, by age group, year, sex and setting

**British Columbia**

Year - Sex	Age group, years											
	10-19	20-29	30-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
2014 M	3.4	12.0	17.4	28.7	42.1	72.3	130.1	207.1	321.8	650.4	1058.5	3569.9
2014 F	2.1	5.7	11.4	17.8	21.5	42.2	64.8	105.0	193.6	390.4	700.6	3565.6
2015 M	5.7	15.2	23.0	30.6	45.3	71.4	117.7	180.6	331.9	593.5	1141.2	3871.7
2015 F	5.3	5.1	9.0	18.0	25.4	41.5	65.8	128.3	211.3	387.6	821.1	3735.1
2016 M	5.7	17.4	23.2	30.4	52.3	69.4	120.2	219.1	368.1	623.7	1144.2	3884.9
2016 F	4.1	7.9	12.7	15.7	27.3	45.4	87.0	121.8	216.2	402.8	821.9	3640.3
2017 M	6.8	19.6	24.6	38.4	59.3	81.9	136.6	204.4	356.0	625.7	1204.4	4078.4
2017 F	6.8	11.9	14.5	15.7	30.3	47.5	71.6	112.6	237.1	417.3	764.6	3922.6
2018 M	14.7	44.1	59.3	84.7	84.5	120.1	165.2	236.4	356.4	583.9	1108.3	3894.6
2018 F	6.3	16.5	25.4	22.6	37.5	61.4	71.4	142.2	223.3	393.4	800.2	3813.0
2019 M	8.6	52.5	77.8	78.7	109.0	143.4	174.4	239.2	375.7	622.5	1107.4	3897.2
2019 F	5.5	19.6	33.9	35.5	51.7	62.5	84.8	130.3	204.7	376.5	852.9	3784.0

**Scotland**

Year - Sex	Age group, years											
	10-19	20-29	30-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
2014 M	6.1	9.7	23.2	49.1	74.0	94.1	160.7	255.0	400.3	779.8	1482.4	4698.0
2014 F	5.7	8.8	12.5	29.6	47.6	67.6	116.2	214.0	330.5	594.6	1259.0	4883.8
2015 M	5.1	12.4	26.0	52.3	74.1	100.9	173.4	252.2	441.6	879.3	1611.8	5179.1
2015 F	5.7	8.4	18.2	35.1	46.0	76.4	125.4	199.7	359.8	673.6	1280.7	5466.3
2016 M	11.3	13.6	25.5	62.5	81.3	121.6	166.0	263.4	472.4	810.8	1476.1	4873.3
2016 F	4.6	6.8	15.6	28.4	54.2	78.4	128.4	247.7	351.7	674.0	1303.5	5160.5
2017 M	5.8	9.7	26.7	49.5	80.3	118.1	154.4	260.1	418.7	784.6	1627.8	5164.6
2017 F	6.8	8.7	19.2	32.6	44.1	64.4	131.8	228.9	352.6	643.7	1362.6	5468.7
2018 M	5.1	14.7	22.7	46.9	74.2	110.3	164.9	261.0	461.3	726.9	1588.7	5070.2
2018 F	8.6	10.7	17.8	33.3	57.3	83.3	126.4	214.4	363.6	651.4	1316.2	5397.7
2019 M	7.5	11.7	24.2	49.8	81.2	101.1	137.9	265.5	434.7	764.0	1457.6	4825.2
2019 F	4.3	6.9	17.5	41.2	44.5	76.3	118.6	205.2	354.2	615.6	1215.0	5181.3

**England**

Year - Sex	Age group, years											
	10-19	20-29	30-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
2014 M	6.6	10.5	17.3	29.3	45.1	63.8	101.1	183.9	311.8	611.6	1214.9	4590.9
2014 F	4.9	6.7	12.3	21.1	29.2	46.9	76.9	144.5	238.6	481.7	984.1	4914.9
2015 M	6.2	11.2	17.4	32.8	47.8	72.2	112.2	191.6	320.3	626.8	1294.5	5030.7
2015 F	5.8	7.6	11.4	20.0	31.0	51.0	80.0	141.8	251.4	491.2	1035.7	5522.3
2016 M	5.4	11.2	17.2	34.6	49.5	73.0	117.5	200.6	341.3	639.7	1337.0	4954.9
2016 F	5.1	8.1	13.9	24.1	32.7	52.2	88.8	156.3	262.8	514.0	1044.9	5350.0
2017 M	6.7	11.4	18.7	31.8	54.8	73.0	111.9	197.3	349.1	635.2	1341.2	5020.2
2017 F	4.4	7.1	12.1	21.0	34.3	51.0	85.6	148.8	261.8	482.0	1057.9	5493.4
2018 M	5.2	11.5	18.2	33.5	50.1	79.0	118.2	199.6	357.1	635.1	1328.5	4992.4
2018 F	4.4	7.0	12.5	21.9	35.3	54.7	87.1	149.2	261.8	493.6	1062.4	5487.5
2019 M	6.9	12.3	19.4	30.9	51.3	75.8	121.3	191.1	356.0	609.9	1265.7	4863.9
2019 F	4.2	7.3	12.9	20.7	32.8	52.5	82.4	148.6	256.3	479.7	1009.7	5147.2

Table S9. Methods used to identify compensated cirrhosis and end-stage liver disease (ESLD) at SVR achievement, by setting

	Setting		
	British Columbia	Scotland	England
Compensated cirrhosis	<p>Pre-SVR emergency department visits, inpatient and outpatient hospital admissions data using the following ICD10 codes:  <u>K703</u> (alcohol cirrhosis of liver); <u>K717</u> (Toxic liver disease with fibrosis and cirrhosis of liver); <u>K746</u> (other and unspecified cirrhosis of liver); and <u>K766</u> (portal hypertension)                      Note that if an ESLD code is also present, the individual will be assigned to the ESLD group.</p>	<p>Clinical diagnosis of cirrhosis without record of ESLD (derived from medical notes)</p>	<p>Clinical diagnosis of cirrhosis without record of ESLD (derived from medical notes)</p>
End stage liver disease (ESLD)	<p>Pre-SVR emergency department visits, cancer registrations, inpatient and outpatient hospital admissions data using the following ICD10 codes:  <u>K721</u> (chronic hepatic failure); <u>K729</u> (hepatic failure, unspecified); <u>K704</u> (alcoholic hepatic failure); <u>K767</u> (hepatorenal syndrome); <u>I850</u> and <u>I983</u> (oesophageal varices with bleeding); <u>R18</u> (ascites); <u>C22</u> (primary liver cancer)                      Note that, because ascites can have non-hepatic causes, R18 was only included if accompanied by a corroborating liver code (K70-K77).</p>	<p>Diagnosis of: a) bleeding varices; b) ascites; c) hepatic encephalopathy; or d) hepatocellular carcinoma, derived from information recorded in medical notes.</p>	<p>Diagnosis of: a) bleeding varices; b) ascites; c) hepatic encephalopathy; or d) hepatocellular carcinoma, derived from information recorded in medical notes.</p>

N.B. pre-cirrhosis defined by the absence of compensated cirrhosis and ESLD  
HCC=hepatocellular carcinoma; ICD= International Classification of Disease

Table S10. ICD codes used to define cause-specific categories of death

<b>Cause of death</b>	<b>ICD definition</b>
Primary liver cancer	<u>C22</u> : Malignant neoplasm of liver and intrahepatic bile ducts
Liver failure	<u>K70</u> : Alcohol liver disease <u>K71-K77</u> : Non-alcoholic liver disease <u>B15-B19</u> : Viral hepatitis <u>B942</u> : Sequelae of viral hepatitis <u>I850, I982 and I983</u> : Oesophageal varices
Drug-related	<u>F11-F16 and F19</u> : Mental/behavioural disorders due to psychoactive substance use <u>X40-X44</u> : Unintentional drug poisoning <u>X60-X64</u> : Intentional drug poisoning <u>Y10-Y14</u> : Drug-related poisoning of undetermined intent
External causes	<u>V00-X39 and X45-X59</u> : Accidents, excluding unintentional drug poisoning <u>X65-X84</u> : Suicide, excluding intentional drug-related overdoses <u>X85-Y09</u> : Homicide <u>Y15-Y99</u> : Other external cause
Extrahepatic cancer	<u>C00-D49</u> : Neoplasms (excluding primary liver cancer, C22)
Diseases of circulatory system	<u>I00-I99</u> : Diseases of the circulatory system (excluding oesophageal varices; I850; I982, I983).
Other (non of the above)	All ICD-10 codes not listed above

ICD-10: International Classification of Diseases

Table S11: ICD-10 codes used to identify hospital admissions relating to alcohol and substance use.

	ICD-10 codes
Alcohol use*	<p><u>E24.4</u>: alcohol-induced Pseudo Cushing's syndrome</p> <p><u>E51.2</u>: Wernicke's encephalopathy</p> <p><u>F10</u>: Mental and behavioural disorders due to use of alcohol</p> <p><u>G31.2</u>: Degeneration of nervous system due to alcohol</p> <p><u>G62.1</u>: Alcoholic polyneuropathy</p> <p><u>G72.1</u>: Alcoholic myopathy</p> <p><u>I42.6</u>: Alcoholic cardiomyopathy</p> <p><u>K29.2</u>: Alcoholic gastritis</p> <p><u>K70</u>: Alcoholic liver disease</p> <p><u>K86.0</u>: Alcohol-induced chronic pancreatitis</p> <p><u>PO4.3</u> AND <u>O35.4</u>: Fetus and newborn affected by maternal use of alcohol</p> <p><u>Q86.0</u>: Fetal alcohol syndrome</p> <p><u>R78.0</u>: Excessive blood level of alcohol</p> <p><u>T51.0</u> and <u>T51.9</u>: Toxic effect of alcohol</p> <p><u>X45</u>, <u>X65</u> and <u>Y15</u>: Alcohol poisoning</p> <p><u>Y90</u>: High blood alcohol level</p> <p><u>Y91</u>: Evidence of alcohol involvement determine by level of intoxication</p>
Substance use	<p><u>F11-F19</u>: Mental and behaviour disorders due to psychoactive substance use</p> <p><u>T40</u>: poisoning by narcotics and psychodysleptics</p>

\* comprised of conditions wholly attributed to alcohol use; identified in a previous review by NHS National Services Scotland. Available at: <https://www.scotpho.org.uk/publications/reports-and-papers/alcohol-attributable-mortality-and-morbidity-alcohol-population-attributable-fractions-for-scotland/>

**Table S12: Standard populations underpinning standardised mortality rates.**

Values represent the proportion of follow-up time accrued in each age-sex group in British Columbia, by disease stage

Age group	Sex	Liver disease severity group			All patients
		Pre-cirrhosis	Cirrhosis	ESLD	
<20	Male	0.000	0.000	0.000	0.000
	Female	0.000	0.000	0.000	0.000
20-29	Male	0.006	0.000	0.000	0.005
	Female	0.009	0.000	0.001	0.007
30-39	Male	0.031	0.015	0.012	0.028
	Female	0.026	0.003	0.003	0.022
40-44	Male	0.028	0.011	0.012	0.025
	Female	0.020	0.005	0.005	0.017
45-49	Male	0.051	0.024	0.036	0.047
	Female	0.028	0.013	0.022	0.026
50-54	Male	0.092	0.091	0.055	0.089
	Female	0.049	0.037	0.049	0.048
55-59	Male	0.142	0.143	0.148	0.143
	Female	0.074	0.081	0.076	0.075
60-64	Male	0.179	0.216	0.229	0.187
	Female	0.078	0.097	0.126	0.083
65-69	Male	0.090	0.130	0.112	0.096
	Female	0.040	0.054	0.052	0.043
70-74	Male	0.025	0.034	0.030	0.026
	Female	0.010	0.021	0.012	0.011
75-79	Male	0.007	0.006	0.004	0.007
	Female	0.008	0.012	0.012	0.009
80+	Male	0.004	0.007	0.003	0.004
	Female	0.004	0.001	0.004	0.003

Table S13: Specification of standardied mortality ratio (SMR) and mortality rate models

Attribute	Modelling SMR	Modelling mortality rate
Regression model:	Poisson	Poisson
Dependent variable:	death (any cause)	death (any cause)
Independent variables:	Acquired age; sex; year; alcohol-related hospital admission; substance use related hospital admission; comorbidity score	Acquired age; sex; year; alcohol-related hospital admission; substance use related hospital admission; comorbidity score
Data structure:	Lexis expansion (split by age group, sex, calendar year)	Lexis expansion (split by age group, sex, calendar year)
Standard errors:	Robust (clustered by individual ID)	Robust (clustered by individual ID)
Offset:	Number of expected deaths (i.e. age/sex/year specific mortality rate for general population * person years of follow-up)	Person years of follow-up
Interpretation of exponentiated beta coefficient:	SMR ratio	Mortality rate ratio

Table S14: Number of deaths in each setting, by cause of death

Cause of death	BC	England	Scotland	Total
All causes	821	309	442	1572
Liver cancer	116	83	51	250
Liver failure	130	112	44	286
Drug-related	183	10	190	383
External causes	33	6	28	67
Extrahepatic cancer	123	24	34	181
Circulatory diseases	104	36	36	176
Other	132	38	59	229

Table S15. Factors associated with all-cause mortality rate in **univariable** analysis, by liver disease severity and setting

Characteristic	British Columbia; N= 11,942							Scotland; N= 7691						England; N=2157					
	Pre-cirrhosis		Cirrhosis		ESLD		Pre-cirrhosis		Cirrhosis		ESLD		Cirrhosis		ESLD				
	Mortality rate ratio (95%CI)	P																	
Year cure achieved	1.11 (1.03 to 1.20)	0.004	0.91 (0.77 to 1.07)	0.24	0.82 (0.73 to 0.91)	<0.001	1.05 (0.97 to 1.14)	0.24	1.06 (0.95 to 1.19)	0.32	0.98 (0.79 to 1.23)	0.89	1.09 (0.93 to 1.27)	0.26	0.94 (0.85 to 1.03)	0.19			
Age, per 10 year increase	1.22 (1.11 to 1.34)	<0.001	1.29 (0.98 to 1.69)	0.07	1.28 (1.03 to 1.58)	0.024	1.19 (1.05 to 1.34)	0.006	1.13 (0.97 to 1.31)	0.12	1.17 (0.91 to 1.51)	0.21	1.37 (1.13 to 1.66)	0.001	1.08 (0.90 to 1.30)	0.42			
Gender	Male	REF (1.00)		REF (1.00)															
	Female	0.69 (0.56 to 0.84)	<0.001	0.57 (0.35 to 0.92)	0.02	0.76 (0.57 to 1.02)	0.07	0.69 (0.50 to 0.95)	0.02	0.89 (0.62 to 1.28)	0.54	0.79 (0.43 to 1.42)	0.43	0.87 (0.57 to 1.33)	0.53	1.07 (0.77 to 1.47)	0.70		
Hospital admission for alcohol use	No	REF (1.00)		REF (1.00)															
	Yes (not recent)	1.71 (1.28 to 2.30)	<0.001	1.43 (0.73 to 2.77)	0.30	1.22 (0.81 to 1.85)	0.34	1.44 (1.01 to 2.07)	0.04	1.37 (0.87 to 2.15)	0.18	0.73 (0.28 to 1.94)	0.53	1.46 (0.81 to 2.62)	0.21	0.73 (0.42 to 1.28)	0.28		
	Yes (recent)	4.00 (3.07 to 5.21)	<0.001	2.45 (1.47 to 4.06)	0.001	1.38 (1.00 to 1.90)	0.05	2.73 (1.88 to 3.96)	<0.001	2.06 (1.44 to 2.95)	<0.001	1.66 (0.95 to 2.89)	0.07	1.91 (1.21 to 2.99)	0.005	1.79 (1.32 to 2.42)	<0.001		
Hospital admission for substance use	No	REF (1.00)		REF (1.00)															
	Yes (not recent)	2.05 (1.61 to 2.60)	<0.001	1.16 (0.62 to 2.17)	0.64	1.14 (0.73 to 1.77)	0.57	1.85 (1.34 to 2.56)	<0.001	1.50 (1.02 to 2.20)	0.04	1.06 (0.51 to 2.24)	0.87	1.80 (1.04 to 3.10)	0.04	1.08 (0.61 to 1.92)	0.79		
	Yes (recent)	3.93 (3.17 to 4.87)	<0.001	1.83 (0.92 to 3.65)	0.09	1.65 (1.12 to 2.43)	0.01	3.08 (2.26 to 4.19)	<0.001	2.62 (1.83 to 3.74)	<0.001	1.96 (1.09 to 3.54)	0.03	1.96 (1.32 to 2.91)	0.001	1.85 (1.37 to 2.49)	<0.001		
Charlson comorbidity index	0.80 (0.78 to 0.82)*	<0.001	0.35 (0.21 to 0.58)**	<0.001	1.24 (1.16 to 1.34)	<0.001	1.34 (1.19 to 1.50)	<0.001	0.25 (0.17 to 0.38)**	<0.001	1.18 (0.97 to 1.43)	0.09	0.87 (0.81 to 0.92)*	<0.001	1.04 (0.94 to 1.16)	0.41			

\* First degree fractional polynomial : power = -1

\*\* First degree fractional polynomial : power = -2

Table S16. Factors associated with standardised mortality ratio in **univariable** analysis, by liver disease severity and setting

Characteristic	British Columbia; N= 11,942						Scotland; N= 7691						England; N=2157					
	Pre-cirrhosis		Cirrhosis		ESLD		Pre-cirrhosis		Cirrhosis		ESLD		Cirrhosis		ESLD			
	SMR ratio (95%CI)	P	SMR ratio (95%CI)	P	SMR ratio (95%CI)	P	SMR ratio (95%CI)	P	SMR ratio (95%CI)	P	SMR ratio (95%CI)	P	SMR ratio (95%CI)	P	SMR ratio (95%CI)	P		
Year cure achieved	1.07 (0.99 to 1.16)	0.09	0.86 (0.73 to 1.02)	0.09	0.77 (0.69 to 0.87)	<0.001	1.04 (0.94 to 1.15)	0.42	1.04 (0.91 to 1.19)	0.53	1.11 (0.88 to 1.41)	0.38	1.01 (0.86 to 1.18)	0.94	0.83 (0.75 to 0.82)	0.001		
Age, per 10 year increase	0.54 (0.50 to 0.59)	<0.001	0.54 (0.43 to 0.69)	<0.001	0.54 (0.45 to 0.66)	<0.001	0.57 (0.51 to 0.64)	<0.001	0.99 (0.99 to 0.99)**	<0.001	0.52 (0.41 to 0.65)	<0.001	0.56 (0.47 to 0.67)	<0.001	0.45 (0.38 to 0.53)	<0.001		
Gender	Male	REF (1.00)		REF (1.00)		REF (1.00)		REF (1.00)		REF (1.00)		REF (1.00)		REF (1.00)		REF (1.00)		
	Female	1.10 (0.89 to 1.36)	0.38	0.89 (0.54 to 1.46)	0.64	1.14 (0.81 to 1.60)	0.44	0.92 (0.65 to 1.30)	0.62	0.97 (0.64 to 1.47)	0.88	0.94 (0.47 to 1.88)	0.86	0.96 (0.61 to 1.51)	0.85	1.15 (0.79 to 1.66)	0.48	
Hospital admission for alcohol use	No	REF (1.00)		REF (1.00)		REF (1.00)		REF (1.00)		REF (1.00)		REF (1.00)		REF (1.00)		REF (1.00)		
	Yes (not recent)	2.49 (1.84 to 3.37)	<0.001	1.93 (0.98 to 3.81)	0.06	1.44 (0.93 to 2.24)	0.11	1.73 (1.20 to 2.50)	0.003	1.75 (1.08 to 2.83)	0.02	0.98 (0.35 to 2.77)	0.97	1.66 (0.91 to 3.06)	0.10	1.01 (0.56 to 1.81)	0.98	
	Yes (recent)	4.92 (3.59 to 6.74)	<0.001	3.55 (2.10 to 5.98)	<0.001	1.95 (1.39 to 2.76)	<0.001	3.27 (2.22 to 4.83)	<0.001	2.95 (2.00 to 4.36)	<0.001	2.54 (1.38 to 4.70)	0.003	2.61 (1.64 to 4.17)	<0.001	3.07 (2.21 to 4.27)	<0.001	
Hospital admission for substance use	No	REF (1.00)		REF (1.00)		REF (1.00)		REF (1.00)		REF (1.00)		REF (1.00)		REF (1.00)		REF (1.00)		
	Yes (not recent)	3.56 (2.79 to 4.54)	<0.001	1.75 (0.93 to 3.32)	0.08	1.72 (1.06 to 2.78)	0.03	2.65 (1.91 to 3.69)	<0.001	2.46 (1.64 to 3.68)	<0.001	2.60 (1.19 to 5.65)	0.02	2.47 (1.39 to 4.37)	0.002	1.71 (0.93 to 3.12)	0.08	
	Yes (recent)	7.43 (5.94 to 9.30)	<0.001	3.38 (1.68 to 6.80)	0.001	2.77 (1.83 to 4.19)	<0.001	4.76 (3.46 to 6.53)	<0.001	4.49 (3.06 to 6.59)	<0.001	3.89 (2.04 to 7.42)	<0.001	2.86 (1.91 to 4.28)	<0.001	3.14 (2.27 to 4.34)	<0.001	
Charlson comorbidity index	0.38 (0.33 to 0.43)*	<0.001	1.27 (1.11 to 1.45)	<0.001	1.21 (1.12 to 1.31)	<0.001	1.24 (1.10 to 1.39)	<0.001	1.29 (1.14 to 1.45)	<0.001	1.01 (0.79 to 1.30)	0.94	1.15 (1.01 to 1.30)	0.03	0.90 (0.79 to 1.03)	0.14		

\* First degree fractional polynomial : power = -0.5

\*\* First degree fractional polynomial : power =3

**Interpretation:**

The Standardised mortality ratio (SMR) is the ratio of observed to expected death, where expected deaths indicate the number of deaths that would have occurred if cured patients exhibited the same age/sex/year specific mortality rates as the corresponding general population.

The *SMR ratio* indicates the ratio of SMR in the group of interest relative to the reference group. For example, if the SMR ratio for individuals with a recent substance use hospital admission is 3.0, this means the SMR is three time higher in this group versus individuals with no previous admission.

Table S17. Factors associated with standardised mortality ratio in multivariable analysis, by liver disease severity and setting

Characteristic	British Columbia; N= 11,942						Scotland; N= 7691						England; N=2157					
	Pre-cirrhosis		Cirrhosis		ESLD		Pre-cirrhosis		Cirrhosis		ESLD		Cirrhosis		ESLD			
	SMR ratio (95%CI)	P	SMR ratio (95%CI)	P	SMR ratio (95%CI)	P	SMR ratio (95%CI)	P	SMR ratio (95%CI)	P	SMR ratio (95%CI)	P	SMR ratio (95%CI)	P	SMR ratio (95%CI)	P		
Year cure achieved	1.06 (0.98 to 1.15)	0.15	0.86 (0.73 to 1.02)	0.08	0.79 (0.70 to 0.89)	<0.001	0.98 (0.90 to 1.07)	0.66	0.96 (0.85 to 1.09)	0.55	0.99 (0.80 to 1.24)	0.95	1.03 (0.88 to 1.20)	0.72	0.93 (0.84 to 1.03)	0.18		
Age, per 10 year increase	0.61 (0.56 to 0.67)	<0.001	0.61 (0.48 to 0.78)	<0.001	0.62 (0.50 to 0.76)	<0.001	0.63 (0.55 to 0.71)	<0.001	0.57 (0.50 to 0.66)	<0.001	0.58 (0.44 to 0.76)	<0.001	0.57 (0.47 to 0.69)	<0.001	0.52 (0.43 to 0.64)	<0.001		
Gender	Male	REF (1.00)		REF (1.00)														
	Female	1.26 (1.03 to 1.54)	0.03	0.90 (0.56 to 1.47)	0.68	1.34 (0.99 to 1.81)	0.06	1.27 (0.91 to 1.76)	0.16	1.35 (0.92 to 1.97)	0.12	1.31 (0.71 to 2.41)	0.38	1.32 (0.84 to 2.10)	0.23	1.66 (1.18 to 2.32)	0.003	
Hospital admission for alcohol use	No	REF (1.00)		REF (1.00)														
	Yes (not recent)	1.04 (0.75 to 1.44)	0.84	1.53 (0.78 to 3.01)	0.22	1.29 (0.85 to 1.95)	0.23	1.16 (0.80 to 1.67)	0.44	1.21 (0.76 to 1.94)	0.42	0.76 (0.29 to 1.98)	0.57	1.29 (0.70 to 2.39)	0.42	0.73 (0.41 to 1.30)	0.29	
	Yes (recent)	1.93 (1.41 to 2.63)	<0.001	2.39 (1.35 to 4.24)	0.003	1.45 (1.01 to 2.08)	0.04	1.72 (1.14 to 2.60)	0.01	1.53 (1.04 to 2.25)	0.03	1.56 (0.86 to 2.83)	0.15	1.61 (0.97 to 2.66)	0.07	1.64 (1.16 to 2.31)	0.005	
Hospital admission for substance use	No	REF (1.00)		REF (1.00)														
	Yes (not recent)	2.24 (1.71 to 2.92)	<0.001	1.08 (0.56 to 2.07)	0.82	1.33 (0.85 to 2.09)	0.22	1.93 (1.37 to 2.72)	<0.001	1.58 (1.05 to 2.37)	0.03	1.44 (0.64 to 3.20)	0.38	2.01 (1.11 to 3.61)	0.02	1.20 (0.65 to 2.23)	0.56	
	Yes (recent)	2.91 (2.16 to 3.91)	<0.001	1.51 (0.69 to 3.31)	0.31	1.71 (1.09 to 2.68)	0.02	2.88 (1.99 to 4.15)	<0.001	2.54 (1.69 to 3.82)	<0.001	1.94 (0.98 to 3.83)	0.06	1.74 (1.09 to 2.77)	0.02	1.74 (1.22 to 2.47)	0.002	
Charlson comorbidity index	0.99 (0.98 to 0.99)*	<0.001	1.22 (1.06 to 1.39)	0.004	1.22 (1.14 to 1.31)	<0.001	1.24 (1.10 to 1.41)	0.001	1.36 (1.20 to 1.54)	<0.001	1.14 (0.92 to 1.40)	0.24	1.18 (1.05 to 1.32)	0.004	1.02 (0.91 to 1.15)	0.68		

cells shaded in grey are statistically significant at P<0.05

\* First degree fractional polynomial : power = -2

**Interpretation:**

The Standardised mortality ratio (SMR) is the ratio of observed to expected death, where expected deaths indicate the number of deaths that would have occurred if cured patients exhibited the same age/sex/year specific mortality rates as the corresponding general population.

The *SMR ratio* indicates the ratio of SMR in the group of interest relative to the reference group. For example, if the SMR ratio for individuals with a recent substance use hospital admission is 3.0, this means the SMR is three time higher in this group versus individuals with no previous admission.

Table S18: characteristics of cured hepatitis C patients from a previous population-based study in Scotland in the IFN-free DAA era versus the present analysis

	Previous population-based study (IFN-based era): Scotland*	Present study (IFN-free era): Scottish patients
Number of patients	1824	7691
Cirrhosis, with or without ESLD (%)	5.8	25.7
Age, mean	40.7	46.1
Male (%)	67.9	72.2
Past hospitalisation due to alcohol use (%)	6.9	20.6
Past hospitalisation due to drug use (%)	14.3	34.1
Crude mortality rate	7.1 deaths/1000 PYs	16.1 deaths/1000 PYs
Standardised mortality ratio	1.86 (95%CI:1.49-2.32)	4.53 (95%CI:4.10-5.00)

\* Innes H, et al. J Hepatol. 2017;66:19-27.

## **APPENDIX A:**

### **Data linkage- missing data perspective.**

#### Scotland

Patient records held on the Scottish HCV clinical database were linked to mortality and hospital admission data. This linkage was performed using the Community Health Index (CHI) number, a unique identifier allocated to every patient in NHS Scotland. The CHI number is recorded for >95% of records in the Scottish HCV Clinical database. Thus, records from the HCV clinical database were linked deterministically to records in national health registries (e.g. SMR01 and the mortality register) via matching CHI number. All linkages were approved by the Public Health Scotland Privacy Benefit Panel (application number:156-0457).

On the latest version of the HCV Scottish clinical database (downloaded April 2021) there were 12,395 records of antiviral therapy resulting in a sustained viral response. Of these, only 72 did not have a valid CHI number recorded. These individuals have unknown mortality status therefore and were excluded from this study.

#### England

HCVRUK study participants with cirrhosis were linked to health registries held by NHS digital. Individuals were initially linked to the Patient Demographic Service (PDS) register using NHS number and date of birth. Record linkage data were only provided for patients who could be “traced” on the PDS.

Of 2277 individuals meeting our inclusion criteria for this study, 2157 (95%) individuals were traced on the PDS. The remaining 117 participants were excluded from the study. The main explanation for why 117 participants (5%) could not be traced on the PDS is likely to be data input errors for NHS number and date of birth, as these were entered manually into the HCVRUK database.

This linkage was approved by the Independent Group Advising on the Release of Data (IGARD), application number: NIC-72626.

#### British Columbia:

In BC, the Personal Health Number (a unique patient identifier in BC) for individuals with a HCV laboratory test are sent to ministry of health routinely.

At ministry of health, these personal health numbers are linked deterministically to numerous administrative health registers, including the mortality register.

The cohort for the present study was derived from Personal Health numbers sent to the Ministry of Health for routine record linkage. By definition therefore, all individuals in our cohort have a valid PHN; thus, there should be no missing information on mortality status or other health registry-derived data variables.

However, some HCV laboratory tests do not provide sufficient information for the personal health number to be established – thus, there is potential for some SVR patients to be excluded from our cohort.

For more information regarding the linkage process, see Janjua NZ et al. PMID: 26954020.

#### **APPENDIX B: Lexis expansion:**

Lexis expansion was performed to update background mortality risk as individuals age and progress through calendar years.

For example, suppose an individual was born on 1<sup>st</sup> May 1960, achieved HCV cure on 15<sup>th</sup> January 2015 and died on 15<sup>th</sup> January 2019. In this case, the total follow-up time would be four years.

Before lexis expansion, this individual would be analysed as a single row of data, with a background mortality rate corresponding to the patient's age group and calendar year at the time cure was achieved.

After lexis expansion, this single row of data is split into 6 records, each representing a unique combination of age group and calendar year (see Table below).

Note that due to aging, the number of expected deaths (calculating by multiplying the general population mortality rate by the duration of follow-up) for this hypothetical patient is higher after the lexis expansion (0.0287) versus before the lexis expansion (0.019).

Of note, in lexis expansion, single calendar years were used to split follow-up; i.e. 2014; 2015; 2016; 2017; 2018 and 2019.

The age group splits were: <20; 20-29; 30-39; 40-44; 45-49; 50-54; 55-59; 60-64; 65-69; 70-74; 75-79; and 80+ years.

A more general explanation of lexis expansion can be found in: Essential medical statistics book, Kirkland and Sterne; Chapter 24.

**Lexis Expansion: hypothetical example**

*Before lexis expansion.*

ID number	DOB	age at cure	date of cure	date of death	time start, years	time stop, years	Mortality event	Follow-up duration, years	age group	calendar year	acquired age	GP mortality rate	Expected deaths
100	01/05/1960	54.7	15/01/2015	15/01/2019	0	4	Yes	4	50-54	2015	54.7	0.0048	0.019

*After lexis expansion for age group and sex*

ID number	DOB	age at cure	date of cure	date of death	time start, years	time stop, years	Mortality event	Follow-up duration, years	age group	calendar year	acquired age	GP mortality rate	Expected deaths
100	01/05/1960	54.7	15/01/2015	15/01/2019	54.71	55.00	No	0.29	50-54	2015	54.71	0.0048	0.001397
100	01/05/1960	54.7	15/01/2015	15/01/2019	55.00	55.67	No	0.67	55-59	2015	55.00	0.0074	0.004974
100	01/05/1960	54.7	15/01/2015	15/01/2019	55.67	56.67	No	1	55-59	2016	55.67	0.0076	0.007619
100	01/05/1960	54.7	15/01/2015	15/01/2019	56.67	57.67	No	1	55-59	2017	56.67	0.0071	0.007145
100	01/05/1960	54.7	15/01/2015	15/01/2019	57.67	58.67	No	1	55-59	2018	57.67	0.0073	0.007333
100	01/05/1960	54.7	15/01/2015	15/01/2019	58.67	58.71	Yes	0.04	55-59	2019	58.67	0.0068	0.000257